S100A11 Antibody

1. Our present study indicated that S100A11 promotes EMT through accumulation of TGF-beta1 expression, and TGF-beta1-induced upregulation of p-SMAD2 and 3. PMID: 29569474
2. Results show that S100A11 expression is up-regulated by BC200 through stabilizing its mRNA and that S100A11 critically mediates the ability of BC200 RNA to induce cancer cell migration and invasion. PMID: 28277927
3. identified as a new regulator of Aldo-induced collagen production in human cardiac fibroblasts. PMID: 28739510
4. Furthermore, we identify flotillin-1 (FLOT1) and histone H1 as downstream factors for cytoplasmic and nuclear pathway of S100A11, which are required for LASP1-S100A11 axis-mediated epithelial-mesenchymal transition and colorectal cancer progression. PMID: 27181092
5. In patients with rheumatoid arthritis, S100A11 is up-regulated and is associated with inflammation and disease activity. PMID: 28446208
6. S100A11 overexpression correlates with an aggressive malignant phenotype and may constitute a novel prognostic factor for HGSC PMID: 26574635
7. we studied S100A11 and noted knockdown of S100A11 using short hairpin RNA, which inhibited proliferation, invasion, and migration of renal carcinoma cells as well as increased expression of E-cadherin and decreased expression of epidermal growth factor receptor/Akt in renal carcinoma cells. Therefore, S100A11 may be a key molecular target for treating renal carcinoma. PMID: 28513300
8. higher S100A11 expression was associated with statistically significant decrease in disease-free survival in clear cell renal cell carcinoma PMID: 26472670
9. the up-regulation of S100A11 plays a role in tumor progression, particularly in KRAS-mutated lung adenocarcinomas PMID: 26544866
10. metastatic cancer cells have elevated rate of cell injury and they rely on the S100A11-ANXA2 complex to enable cell membrane repair. S100A11 in a complex with Annexin A2 helps reseal the plasma membrane. PMID: 24806074
11. All three markers correlated significantly with regional lymph node metastasis: FXYD3 (p = 0.0110), S100A11 (p = 0.0071), and GSTM3 (p = 0.0173) in colon cancer lymphatic metastasis. PMID: 22430872
12. The EGFRvIII-STAT3 pathway promotes cell migration and invasion by upregulating S100A11 in hepatocellular carcinoma. PMID: 24376686
13. Proteomic data suggest a limited protein set is involved in SET- (template activating factor-I-) mediated cytotoxicity of TCE (trichloroethylene) in hepatocytes; this set includes CFL1 (cofilin 1), PRDX2 (peroxiredoxin 2), and S100-A11 (calgizzarin). PMID: 24631019
14. Our data indicate that S100A11 overexpression exerts a protumoral functional role in papillary thyroid carcinoma pathogenesis. PMID: 23928665
15. Data suggest that S100A11 is involved in maintenance of p21-CIP1 (cyclin-dependent kinase inhibitor 1A) protein stability (up-regulation; down-regulation) and appears to function as inhibitor of apoptosis in keratinocytes. PMID: 23745637
16. the structure of human calcium-bound S100A11. PMID: 22903637
17. Endometrial S100A11 is a crucial intermediator in EGF-stimulated embryo adhesion, endometrium receptivity, and immunotolerance via affecting Ca2+ uptake and release from intracellular Ca2+ stores. PMID: 22869607
18. Using transcriptional signatures of blood samples,identified S100A11 as a potential diagnostic marker of infective endocarditis, and AQP9 as a potential prognostic factor. PMID: 22319637
19. The expression level of S100C in lung cancer tissue was lower than that in ambient tissue. PMID: 18589612
20. investigated S100A11 expression in various subtypes of lung cancer and explored its role in cell proliferation. PMID: 21861103
21. S100A11 mediates HIMF-induced smooth muscle cell migration, vesicular exocytosis, and nuclear activation. PMID: 21139050
22. Data support that S100A11 is a novel diagnostic marker in breast carcinoma. PMID: 20372844
23. S100C is a new tumor marker protein, the expression of which significantly decreases after malignant transformation of human tissues. PMID: 11873942
24. S100Cis a key mediator of the Ca(2+)-induced growth inhibition of human keratinocytes in culture, and may be mediate growth regulation in vivo as well. PMID: 14623863
25. that redistribution along microtubules is a mechanism whereby S100A11 is positioned at the cell periphery in preparation for transglutaminase-dependent crosslinking. PMID: 14962086
26. Up-regulation of S100A11 was associated with the development of lymph node metastases in gastric cancer PMID: 15138568
27. Of several tested, only an N-terminal peptide with 19 amino acid residues induces apoptosis in human keratinocyte and squamous-cell carcinoma cell lines PMID: 15241500
28. findings suggest that S100A11 has an anti-apoptotic function and is related to the process of growth of human uterine leiomyoma PMID: 15322223
29. Down-regulation of S100C is associated with bladder cancer progression PMID: 15701847
30. Expression of S100A11, a putative tumor suppressor gene, is increased in the early stage of pancreatic carcinogenesis and decreased during subsequent progression to cancer. PMID: 17000675
31. S100C/A11-mediated pathway is at least partly involved in conferring upon human squamous cell cancers resistant to TGFbeta-induced growth suppression PMID: 17476473
32. The results indicated that the upregulation of S100A11 expression in non-small cell lung cancer tissues was significantly associated with higher tumor-node-metastasis stage (P = 0.001) and positive lymph node status PMID: 17537172
33. Proteomic mapping using a selective subcellular extraction kit revealed S100A11 as a new member of the S100 protein family modulated by glucocorticoids in keratinocytes. PMID: 17624315
34. Ca(2+)-dependent binding of S100A11 to ANXA1 facilitated the binding of the latter to cPLA(2), resulting in inhibition of cPLA(2) activity PMID: 17932043
35. These findings indicate that S100A11 plays a dual role in growth regulation of epithelial cells. PMID: 17978094
36. These findings suggest S100A11 could be helpful in the pathological study of colorectal cancer, especially for the classification of different stages in colorectal cancer. PMID: 18340452
37. S100/A11 and p21 gene expression was also found to be significantly lower in acute and chronic atopic dermatitis skin. PMID: 18385759
38. S100A11 targets Rad54B to sites of DNA DSB repair sites and has a role in p21-based regulation of cell cycle PMID: 18463164
39. Following transformation by transglutaminase 2, S100A11 acquires the capacity to signal through the p38 MAP kinase pathway, accelerate chondrocyte hypertrophy, and couple inflammation with chondrocyte activation to promote progression of osteoarthritis. PMID: 18523305
40. Phosphorylation of S100A11 induces a structural perturbation in the N-terminal edge of helix 1 and enables the phosphoryl group to be exposed to the solvent, allowing it to be recognized by the binding partner, nucleolin. PMID: 18618420
41. S100A11 differentially expressed in primary hepatocellular carcinoma , primary colorectal, and liver PMID: 19048101
42. Inhibition of S100A11 gene expression impairs the ability of keratinocytes to control vaccinia virus replication via downregulation of IFN-lambda receptor IL-10R2. PMID: 19577285
43. Down-regulation of S100C expression is associated with increasing tumor aggressiveness and poor prognosis in bladder cancer patients. PMID: 15701847

Show More

Hide All

HGNC: 10488

OMIM: 603114

KEGG: hsa:6282

STRING: 9606.ENSP00000271638

UniGene: Hs.417004